Here, using a molecular imaging agent selective for HDACs I (isoforms 1–3) quantified across the whole brain24, we show that HDACs I availability is reduced in living patients with AD in brain regions vulnerable to both amyloid-β and tau pathologies. The gene discussed is MAPT; the disease is Alzheimer disease.